Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADK | P55263 | 6/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13392121 | 0.85 | ADORA2A (0.47) | PRMT5WDR77ADORA2AADORA3 | |
| SCHEMBL12253777 | 0.85 | ADORA2A (0.47) | PRMT5WDR77ADORA2AADORA3 | |
| SCHEMBL16502887 | 0.80 | ADORA2A (0.35) | PRMT5WDR77ADORA2ASTING1 | |
| SCHEMBL12253963 | 0.78 | DNPH1 (0.41) | — | |
| Phosphoric Acid SCHEMBL16698786 | 0.77 | POLRMT (0.41) | PRMT5WDR77STING1 | |
| SCHEMBL15682919 | 0.76 | ADORA2A (0.41) | ADORA2AADKADORA3 | |
| SCHEMBL13648824 | 0.75 | ADORA2A (0.34) | PRMT5WDR77ADORA2A | |
| SCHEMBL14141032 | 0.75 | ACVRL1 (0.32) | — | |
| SCHEMBL881381 | 0.74 | ADORA2A (0.40) | ADORA2AADKADORA3 | |
| SCHEMBL10149698 | 0.74 | ADORA2A (0.40) | ADORA2AADKADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012941-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | CDA, PNP, MTAP | PRMT5 2938/4885WDR77 3325/4885ADORA2A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.